infohep news

• Pan-genotypic regimens

  New pangenotypic hepatitis C drug combinations recommended for approval in the European Union

  Keith Alcorn / 26 June 2017

  Two new pangenotypic direct-acting antiviral combinations have received positive opinions from the scientific committee of the European Medicines Agency (the CHMP) and should receive European Union marketing approval in next ...

• Treatment outcomes

  Experts question Cochrane review of hepatitis C treatment

  Keith Alcorn / 15 June 2017

  A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticised by doctors and advocates for its conclusion that there is no ...

• Screening policy

  Six-question risk score can identify HIV-positive gay men needing testing for acute hepatitis C

  Roger Pebody / 13 June 2017

  Six questions can identify HIV-positive gay men who are at elevated risk of having acute (recent) hepatitis C infection and who would benefit from further testing, according to a paper ...

• Interferon-free regimens

  Sofosbuvir plus ribavirin cures teens with genotype 2 or 3 hepatitis C

  Liz Highleyman / 05 June 2017

  A two-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course ...

• Interferon-free regimens

  Indonesian buyers club helps people obtain generic hepatitis C treatment

  Liz Highleyman / 30 May 2017

  A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral (DAA) drugs to treat hepatitis C and is seeing a high cure rate, according to a ...